Connect with us

Hormonal health

Could the first instant at-home test transform how women track their hormones?

Published

on

Eli Health is on a mission to transform female hormone testing with the first FDA-registered instant hormone monitoring system. Co-founder and CEO, Marina Pavlovic Rivas, speaks to Femtech World about making hormone testing more accessible.

The Hormometer, developed by femtech company, Eli Health, enables real-time, saliva testing for instant results, enabling women to monitor their hormonal fluctuations from the comfort of their own home.

Developed over five years, Eli Health raised US$12m in its Series A funding to scale the product, bringing its total funding to US$20m. 

The FDA-registered Hormometer is an at-home needle-free test kit that utilises AI for data-driven insights. Currently, the Hormometer enables women to test their progesterone and cortisol levels, with estradiol testing currently in development.

While women have traditionally paid hundreds of pounds for tests, potentially waiting weeks for test results, Eli’s Hormometer uses computer vision algorithms to analyse the saliva samples, delivering results in 20 minutes at around UD$8 per test.

Marina Pavlovic Rivas, co-founder and CEO of Eli Health, which has 12 patented inventions for hormone monitoring, says that the tests and accompanying app offer insights into women’s health across fertility, menopause, and mental health, enabling improved access and affordability to hormone testing.

“We started the company because we wanted women to have access to the important data when it comes to their health,” Rivas tells Femtech World.

“We realised that when it comes to hormones, this data doesn’t exist at the frequency it’s needed, because you can test your hormones through a lab, but that process takes at best a few days, and on average, a few weeks. It is quite expensive as well.”

Traditional hormone lab tests only provide insight into a certain window of time, Rivas explains, but for women, whose hormones are in constant fluctuation, more consistent monitoring is needed. Hormones like cortisol can also fluctuate up to 100 per cent in one hour, making it difficult to get a full picture. 

“This frequency and cost don’t enable high frequency, long-term testing, which reflects, ultimately, the fluctuations of hormones that happen on a daily basis,” Rivas says.

“Our mission became to create that real-time interface for the human body, so that we can have access to this data at the frequency that matters.”

Using lateral flow assays, the test works by collecting saliva from the tongue. The individual then uploads a picture of the test into the app. 

The app utilises AI-driven insights to provide lab-grade results on hormone levels, along with scores, benchmarks and recommendations to enable women to take action.

“What we enable is not just cheaper, faster testing,” says Rivas. “It’s a very different approach to this type of data. Let’s say you’re measuring your heart rate at the doctor’s office once per year, it’s very different to having it on your wrist at all times with a smart watch. That becomes information that you can use on a daily basis to take actions around your lifestyle, for example, sleep, exercise, and all areas of your health and wellness.”

Explaining the range of markers measured by the Hormometre, she continues: “It touches the typical areas of women’s health – fertility and menopause, but also endocrine conditions and beyond that, some of our hormones, like cortisol, are not reproductive hormones. For us, it was important to include them, because when we speak of hormonal health, it goes beyond reproductive health.

“Some biomarkers like cortisol have a major impact on mental health, how people feel on a daily basis, how they perform at work, but also when they exercise and ultimately, all aspects of their health. It is our mission to enable people to improve their health and performance across all of those different areas.”

Rivas adds: “Around 80 per cent of women will experience symptoms related to hormonal imbalances in their lives, so that’s a very high number of people. When it comes to some hormones like cortisol, there’s one in three people who experience dysregulation. 

“How that translates on a day-to-day basis is that people live with different symptoms that impact their work, that impact personal lives, and having that information enables them to manage those symptoms and even eliminate them.”

It is not only about monitoring hormones, as Rivas highlights, but also about taking preventative action to ward off potential chronic conditions in the future.

“It has been shown in research again and again that dysregulation of some hormones, like cortisol, is also linked to higher probability of developing different conditions, including chronic conditions, heart conditions, cognitive disease and more,” says Rivas.

“Tracking hormones has the double benefit of feeling better today, but also preventing different conditions tomorrow.”

Having recently won the Femtech World Brain and Mental Health Innovation award for its work to help women better understand the impact of hormones on their mental health, EliHealth is now focusing on expanding to other markers.

“We are always focused on making a product that can address the needs of our users, and we’re always very focused on that work. So, to be able to take a step back and have recognition from the industry is meaningful for us in our mission,” Rivas adds.

“The future will be about continuing to focus on that mission of making a real-time interface to the human body by expanding to other hormones and their markers, and ultimately providing that information in real time to our users.”

Eli Health won the Brain and Mental Health Innovation category at the Femtech World Awards 2025. See full winners list here

Insight

PCOS renamed after decade-long campaign to end ‘cyst’ misconception

Published

on

After more than a decade of campaigning, doctors around the world have agreed to rename polycystic ovary syndrome (PCOS).

It is hoped the new name, polyendocrine metabolic ovarian syndrome, or PMOS, will help end the misconception that the condition is all about cysts, which campaigners say has contributed to missed diagnoses and inadequate treatment.

The condition affects one in eight women, or 3.1m women and girls in the UK, and is linked to hormone fluctuations that can affect weight, mental health, skin and the reproductive system.

The renaming was spearheaded by UK patient charity Verity alongside Professor Helena Teede, director of Melbourne’s Monash Centre for Health Research and Implementation.

It followed 14 years of consultation with clinicians and patients around the world.

The new name was published in a consensus statement on May 12 and announced at the European Congress of Endocrinology in Prague.

The paper states that PCOS should now be referred to as PMOS.

“This is a landmark moment that will lead to desperately-needed worldwide advancements in clinical practice and research,” said Professor Teede.

“It was heart-breaking to see the delayed diagnosis, limited awareness and inadequate care afforded those affected by this neglected condition.”

When doctors first named PCOS in 1935, they thought it was mainly caused by physical changes to the ovaries.

Decades of research have since changed that understanding, with clinicians now agreeing the condition is far more complex.

“What we now know is that there is actually no increase in abnormal cysts on the ovary and the diverse features of the condition were often unappreciated,” Professor Teede added.

“A name change was the next critical step towards recognition and improvement in the long term impacts of this condition.”

The exact cause of the condition is still unknown, though it is thought to be linked to abnormal hormone levels and is associated with insulin resistance and raised levels of testosterone and luteinising hormone.

Insulin resistance means the body does not respond properly to insulin, the hormone that helps control blood sugar. Luteinising hormone helps regulate ovulation.

Common symptoms listed by the NHS include irregular periods or no periods at all, difficulty getting pregnant, excessive hair growth, weight gain, thinning hair, oily skin and acne.

Campaigners have acknowledged that the name change could cause temporary confusion.

“Despite decades of tireless advocacy to improve awareness, we recognised that the risk of change would be worth the reward,” said Rachel Morman, chairwoman of Verity.

“This shift will reframe the conversation and demand that it is taken as seriously as the long-term, complex health condition it is.”

It is also unclear if, or when, the NHS will change the language it uses.

An NHS England spokesperson said: “We routinely review and update content on the NHS website to ensure it reflects the latest clinical advice and will carefully consider these recommendations.

“The NHS will also continue our work to improve women’s healthcare, including for this important group, which involves giving women more choice over their care, bringing down waiting times, and delivering more care in communities.”

Continue Reading

Hormonal health

Tampons could track MS nerve damage, study suggests

Published

on

Menstrual fluid collected from tampons could one day provide a simple, non-invasive way to measure a biomarker of nerve damage and potentially track disease activity in neurological conditions such as multiple sclerosis (MS), new research suggests.

Because neurofilament light chain, or NfL, has emerged as a promising biomarker of MS, detecting it in menstrual fluid raises the possibility of monitoring disease activity through the natural monthly cycle of menstruation.

Researchers at Nextgen Jane, in collaboration with Siemens Healthineers, found that NfL, a protein released when nerve cells are damaged, can be reliably detected in tampon-collected menstrual samples.

“Finding that NfL tracks with estrogen levels in menstrual fluid, independent of how much blood is in the sample, tells us there is real biology here, not just contamination,” said Ridhi Tariyal, chief executive and co-founder of Nextgen Jane.

“That changes what this specimen means for neurology.”

In MS, the immune system mistakenly attacks healthy parts of the brain and spinal cord, causing inflammation and damage that can lead to symptoms such as fatigue, numbness, muscle weakness, and problems with balance or vision.

Confirming a diagnosis of MS usually requires a combination of physical and neurological examinations, MRI scans to check for brain and spinal cord damage, and lab tests.

These can include detecting certain proteins in cerebrospinal fluid, the fluid that surrounds the brain and spinal cord, which may indicate inflammation in the brain or spinal cord.

After diagnosis, patients are usually monitored through clinical assessments and routine MRI scans, which help doctors detect changes in disease activity and determine whether treatments are working.

However, MRI assessments can be costly and are usually done once or twice a year, which can prevent doctors from spotting early changes and making timely treatment adjustments.

Because of these challenges, researchers have long sought cost-effective, more accessible biomarkers that could help detect MS earlier, monitor disease activity over time, and evaluate treatment response.

One of the most promising candidates is NfL, a protein found in nerve cell fibres that is released into the bloodstream and cerebrospinal fluid when nerve cells are injured.

To explore whether menstrual fluid could serve as a source for detecting this biomarker and, more broadly, as a non-invasive specimen for monitoring neurological, hormonal and inflammatory signals, researchers analysed 99 tampon-collected menstrual fluid samples from 91 participants.

They used Siemens Healthineers’ highly sensitive NfL assay on its automated testing platform. The team also measured hormonal and inflammatory molecules.

NfL was detected in 98 of the 99 menstrual fluid samples analysed, suggesting the biomarker can be reliably measured in tampon-collected samples.

The researchers also found that NfL levels were associated with estradiol levels, a form of the hormone oestrogen, and that this relationship remained significant even after adjusting for differences in blood content between samples.

By comparison, levels of inflammatory markers were more strongly linked to blood content itself.

According to the researchers, this suggests NfL detection was not merely the result of blood contamination, but may reflect biologically meaningful changes that could potentially be tracked over time through routine menstrual sampling.

Building on these findings, Nextgen Jane is now planning prospective studies to investigate whether menstrual NfL and other neurological proteins can be used to track disease activity over time in conditions such as MS.

“The menstrual cycle provides a built-in longitudinal framework: the same individual, the same biological process, month after month,” said Stephen Gire, chief scientific officer at Nextgen Jane.

“Coupling the NextGen Jane platform with Siemens Healthineers’ highly sensitive NfL assay gives us a path to study neurological biomarker trajectories in a way that has not been possibe before.”

Continue Reading

Fertility

Toxins and climate harms having ‘alarming’ effect on fertility, research warns

Published

on

Simultaneous exposure to toxic chemicals and climate-related heat may be worsening fertility harms across humans and wildlife, research suggests.

The review of scientific literature looks at how endocrine-disrupting chemicals, often found in plastic, together with climate-related effects such as heat stress, are each linked to lower fertility and fecundity, meaning the ability to reproduce, across species including humans, wildlife and invertebrates.

Though the reproductive harms of each issue in isolation are well studied, there is little research on what happens when living organisms are exposed to both.

“Together, the two issues are likely to pose a greater threat to fertility, and the additive effect is “alarming”, said Susanne Brander, a study lead author and courtesy faculty at Oregon State University.

“You’re not just getting exposed to one, but two, stressors at the same time that both may affect your fertility, and in turn the overall impact is going to be a bit worse,” Brander said.

The paper looked at 177 studies.

Shanna Swan, a co-author on the new paper, co-produced a 2017 study that found sperm levels among men in western countries had fallen by more than 50 per cent over four decades. Other research has suggested human fertility has been declining at a similar rate.

The University of Washington’s Institute for Health Metrics and Evaluation has previously said the world was approaching a “low-fertility future”, with more than three quarters of countries below replacement rate by 2050.

The new paper’s authors focused on the effects of endocrine-disrupting chemicals and substances, including microplastics, bisphenol, phthalates and PFAS.

These are thought to cause a range of serious reproductive problems, disrupt hormones and be a potential driver of falling fertility.

Brander said the harms linked to these chemicals are often similar across organisms, from invertebrates to humans.

Phthalates, for example, have been linked to altered sperm shape in invertebrates, spermatogenesis in rodents, meaning sperm production, and reduced sperm counts in humans.

PFAS are also thought to affect sperm quality, and both have been linked to hormone disruption.

The chemicals are widespread in consumer goods, so people are often regularly exposed.

Meanwhile, previous research has shown how rising temperatures, lower oxygen levels and heat stress, among other effects linked to climate change, may also worsen infertility.

Heat stress has been found to affect human hormones, and is linked to spermatogenesis in rodents and bulls.

Research shows temperature also plays a role in sex determination in fish, reptiles and amphibians.

The species has evolved to choose which sex it produces in part based on temperature, and the heating planet can “push it too far in one direction or the other, which overrides that evolutionary benefit”, Brander said.

Similarly, many endocrine disruptors may alter environmental sex determination.

The study set out some of the overlapping effects of chemical exposure and climate change across taxonomic groups, from invertebrates to humans.

In birds, for example, exposure to increased temperature, PFAS, organochlorines and pyrethroids may each individually cause abnormal sperm, increased fledgling mortality, abnormal testes and population decline.

“What happens if they’re exposed to more than one of those stressors at the same time? There has been little exploration of that question.

“Even if there have not been a lot of studies looking at these simultaneously, if you have two different factors that both cause the same adverse effect, then there’s a likelihood that they are going to be additive,” Brander said.

Katie Pelch, a senior scientist with the Natural Resources Defense Council nonprofit, who was not part of the study, said the authors had reviewed high-quality science.

She said she wanted to see more examples of the overlap in impacts, but agreed with the overall premise.

“It is likely [multiple stressors] would have an additive effect, at very least, even if they have different mechanisms of harm,” Pelch added.

The solution to the systemic problems would involve tackling climate change and reducing the use of toxic chemicals.

The study cites the global reduction in the use of DDT and PCBs achieved under the Stockholm Convention as an example of an effective measure, but Brander said much more is needed.

“There is enough evidence in both areas to act to reduce our impact on the planet,” she said.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.